Numerous clinical studies of dual combinations of checkpoint inhibitors are underway, with or without conventional chemotherapy agents, but one of the first Phase Ib studies of a triple combination of immunotherapies in ovarian cancer that includes an investigational cancer vaccine is expected to report initial results in March 2017, and a Phase II trial of another similar triple combination should start in the next several months.
Both triple combinations involve Immunovaccine Inc.’s potential cancer vaccine DPX-Survivac to induce T-cell activation, low doses of cyclophosphamide that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?